Bioforge Hivegen, often known as BioGen, is a multiplanetary genetic engineering conglomerate headquartered in Lausanne, Switzerland. It is best known for its synth specialised in personalised medicine and agricultural optimisation, as well as its organic electronic and cosmetic products. The current conglomerate was formed in 61 BFC when gene-therapy company Bioforge acquired Hivegen, the agricultural technology company famous for saving bees from extinction, when Hivegen was fighting multiple legal battles, most notably for breeding and selling extinct animals on stations outside of the jurisdiction of any animal welfare treaties.

It has divisions producing products in many parts of the bio-economy including mRNA therapies where it competes with Pharmatica Group, but its largest revenue streams are from CRISPR editing applications such as crop improvement, organ transplants, and tailored synthetic organisms. It also a is the leading provider of personalised medicine therapies, with its partial cellular reprogramming product positioned as a more expensive alternative to Pharmatica's senolytic Renovacel.